Diabetes affects more than 12 million  people and is the 7th leading cause of death in the United States.

 

With diabetes primarily affecting the small blood vessels, hyperbaric oxygen therapy has been demonstrated to stimulate angiogenesis to help ameliorate compromised blood flow and prevent organ failure. Research has shown that HBOT can lower blood sugar levels by increasing cellular sensitivity to insulin and skeletal muscle reception of glucose.

 

Furthermore, recent reports have provided evidence towards linking HBOT to regenerating pancreatic islets of Langerhans, thus potentially producing more insulin.

 

HBOT is often beneficial in treating osteomyelitis and cellulitis, in addition to preventing systemic toxicity and permanent disability.

 

With chronic diabetes, impaired circulation reduces wound healing capability and promotes ulcerations. Hyperbaric oxygen therapy increases the amount of oxygen available to ulcerated areas, leading to increased fibroblast activation.